Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with migraine
Headache The Journal of Head and Face Pain2023Vol. 63(7), pp. 953–964
Citations Over TimeTop 10% of 2023 papers
Rikki Mangrum, Maya T. Gerstein, Calvin J. Hall, Dawn C. Buse, Carrie R. Houts, James S. McGinley, Kelly P. McCarrier, Richard B. Lipton, R. J. Wirth
Abstract
The results showed the participants prioritized treatment benefits aligned with existing core clinical outcomes used in migraine research, but also valued benefits that are not typically assessed, such as predictability. Participants also deprioritized important benefits when they believed treatment was unlikely to deliver those outcomes.
Related Papers
- → Hypersensitivity to calcitonin gene-related peptide in chronic migraine(2020)38 cited
- → Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence(2022)17 cited
- → Field Testing Alternative Criteria for Chronic Migraine(2006)58 cited
- → The Face of Chronic Migraine Which Has Started to be Clarified.(2013)4 cited
- → Migraine and the Scope of Homeopathy(2017)1 cited